FDA approves first drug for the 'Jolie gene'

The Food and Drug Administration  on Friday approved AstraZeneca PLC's Lynparza for patients with BRCA gene mutations who have undergone chemotherapy.
Source: the Mail online | Health - Category: Consumer Health News Source Type: news

Related Links:

Publication date: Available online 18 October 2018Source: NeuronAuthor(s): Jane Y. Chen, Carlos A. Campos, Brooke C. Jarvie, Richard D. PalmiterSummaryFood aversions develop when the taste of a novel food is associated with sickness, which often occurs after food poisoning or chemotherapy treatment. We identified calcitonin-gene-related peptide (CGRP) neurons in the parabrachial nucleus (PBN) as sufficient and necessary for establishing a conditioned taste aversion (CTA). Photoactivating projections from CGRPPBN neurons to either the central nucleus of the amygdala or the bed nucleus of the stria terminalis can also induce...
Source: Neuron - Category: Neuroscience Source Type: research
Condition:   Head & Neck Cancer Intervention:   Drug: nanoliposomal irinotecan Sponsors:   National Health Research Institutes, Taiwan;   China Medical University Hospital;   Tri-Service General Hospital;   Taipei Veterans General Hospital, Taiwan;   National Cheng-Kung University Hospital Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   Glioblastoma Multiforme Intervention:   Device: BBB Disruption with Chemotherapy Arm Sponsor:   InSightec Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Conditions:   Carcinoma, Non-Small-Cell Lung;   Chemotherapy, Adjuvant Intervention:   Drug: Shenlingcao Oral Liquid Sponsor:   West China Hospital Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Conditions:   Breast Cancer;   Chemotherapy-induced Alopecia Intervention:   Device: DIGNICAP™ Sponsor:   European Institute of Oncology Completed
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Although outcomes and rates overall toxicity of esophagogastric cancer chemotherapy are similar for men and women, rates of nausea, diarrhea, and hair loss are higher in women, warn UK scientists.Medscape Medical News
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news
Publication date: Available online 18 October 2018Source: Respiratory Medicine Case ReportsAuthor(s): Mari Tone, Nobuyasu Awano, Minoru Inomata, Naoyuki Kuse, Tatsunori Jo, Hanako Yoshimura, Yoshiaki Furuhata, Tamiko Takemura, Toshio Kumasaka, Takehiro IzumoAbstractCorrect staging of lung cancer is important for the selection of the best therapy, but discriminating between lymphadenopathy from lung cancer and from sarcoidosis by imaging examinations is difficult. Additionally, distinguishing lymphadenopathy of sarcoidosis from sarcoid reactions which are sometimes caused by lung cancer is difficult on imaging and pathologi...
Source: Respiratory Medicine Case Reports - Category: Respiratory Medicine Source Type: research
The treatment of relapsed/refractory acute lymphoblastic leukemia (RR-ALL) presents a true clinical challenge. In 2012, a protocol combining bortezomib, dexamethasone, asparaginase, doxorubicin, and vincristine administered to children with RR-ALL was published with encouraging results. Over the past 5 years, we have implemented this protocol in the adult RR-ALL population (#x3e; 18 years) and addressed its feasibility in terms of remission rate and toxicity. Here, we present the results of our experience in 9 patients, all of whom received multiple previous chemotherapy protocols, two of them relapsing after an allogeneic...
Source: Acta Haematologica - Category: Hematology Source Type: research
Conclusion: AM without CCT is associated with poorer survival when compared with CCT.Acta Haematol 2018;140:203 –208
Source: Acta Haematologica - Category: Hematology Source Type: research
Hodgkin lymphoma (HL) is one of the most curable malignancies. Despite its effectiveness, chemotherapy is often associated with adverse events (AEs) such as nausea, anorexia, and impairment of general well-being. Our objective was to assess the extent of medical cannabis use among HL patients and evaluate its efficacy in controlling chemotherapy-related AEs. Patterns of medical cannabis use and efficacy were evaluated using physician-completed application forms, medical files, and patient-completed questionnaires, for all consecutive adult HL patients treated at the Tel-Aviv Medical Center between June 2010 and November 20...
Source: Acta Haematologica - Category: Hematology Source Type: research
More News: AstraZeneca | Chemotherapy | Food and Drug Administration (FDA) | Genetics | Health